Cargando…

Histone methyltransferase SETD2: An epigenetic driver in clear cell renal cell carcinoma

SET domain-containing 2 (SETD2) is a lysine methyltransferase that catalyzes histone H3 lysine36 trimethylation (H3K36me3) and has been revealed to play important roles in the regulation of transcriptional elongation, RNA splicing, and DNA damage repair. SETD2 mutations have been documented in sever...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yu, Mengxue, Qian, Kaiyu, Wang, Gang, Xiao, Yu, Zhu, Yuan, Ju, Lingao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070805/ https://www.ncbi.nlm.nih.gov/pubmed/37025591 http://dx.doi.org/10.3389/fonc.2023.1114461

Ejemplares similares

Epigenetic signature predicts overall survival clear cell renal cell carcinoma
por: Wang, Yejinpeng, et al.
Publicado: (2020)

The immune‐related biomarker TEK inhibits the development of clear cell renal cell carcinoma (ccRCC) by regulating AKT phosphorylation
por: Chen, Siming, et al.
Publicado: (2021)

CTHRC1 Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Kidney Renal Papillary Cell Carcinoma and Kidney Renal Clear Cell Carcinoma
por: Zhou, Fenfang, et al.
Publicado: (2021)

Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma
por: Luo, Yongwen, et al.
Publicado: (2019)

The histone methyltransferase SETD2 negatively regulates cell size
por: Molenaar, Thom M., et al.
Publicado: (2022)

ACAT1 and Metabolism-Related Pathways Are Essential for the Progression of Clear Cell Renal Cell Carcinoma (ccRCC), as Determined by Co-expression Network Analysis
por: Chen, Liang, et al.
Publicado: (2019)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
por: Parker, H, et al.
Publicado: (2016)

The histone methyltransferase Setd2 is indispensable for V(D)J recombination
por: Ji, Zhongzhong, et al.
Publicado: (2019)

Histone methyltransferase SETD1A participates in lung cancer progression
por: Du, Mei, et al.
Publicado: (2021)

Histone Methyltransferase SETD2 Is Required for Porcine Early Embryonic Development
por: Shao, Weini, et al.
Publicado: (2022)

Inhibition of histone methyltransferase SETD8 represses DNA virus replication
por: Chen, Lin, et al.
Publicado: (2022)

SETD3 Methyltransferase Regulates PLK1 Expression to Promote In Situ Hepatic Carcinogenesis
por: Cheng, Meng, et al.
Publicado: (2022)

Downregulation of the histone methyltransferase SETD2 promotes imatinib resistance in chronic myeloid leukaemia cells
por: Sheng, Yaru, et al.
Publicado: (2019)

Lysine methyltransferase SETD6 modifies histones on a glycine-lysine motif
por: Binda, Olivier
Publicado: (2019)

Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers
por: Chen, Rui, et al.
Publicado: (2020)

The histone methyltransferase SETD2 modulates oxidative stress to attenuate experimental colitis
por: Liu, Min, et al.
Publicado: (2021)

Histone lysine methyltransferase Pr‐set7/SETD8 promotes neural stem cell reactivation
por: Huang, Jiawen, et al.
Publicado: (2021)

Histone Methyltransferase SETD1A Induces Epithelial-Mesenchymal Transition to Promote Invasion and Metastasis Through Epigenetic Reprogramming of Snail in Gastric Cancer
por: Wu, Jugang, et al.
Publicado: (2021)

Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma
por: Liu, Weisi, et al.
Publicado: (2015)

The histone methyltransferase Setd8 acts in concert with c-Myc and is required to maintain skin
por: Driskell, Iwona, et al.
Publicado: (2012)

Histone methyltransferase SETD2 coordinates FACT recruitment with nucleosome dynamics during transcription
por: Carvalho, Sílvia, et al.
Publicado: (2013)

The histone lysine methyltransferase SETD8 regulates angiogenesis through HES-1 in human umbilical vein endothelial cells
por: Choi, Dong Kyu, et al.
Publicado: (2020)

KDF1, a Novel Tumor Suppressor in Clear Cell Renal Cell Carcinoma
por: Zheng, Jing-min, et al.
Publicado: (2021)

Novel Biomarkers Associated With Progression and Prognosis of Bladder Cancer Identified by Co-expression Analysis
por: Wang, Yejinpeng, et al.
Publicado: (2019)

Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma
por: Wang, Xingyuan, et al.
Publicado: (2022)

Histone Lysine Methyltransferase SETD2 Regulates Coronary Vascular Development in Embryonic Mouse Hearts
por: Chen, Fengling, et al.
Publicado: (2021)

Discovery of a First-in-Class Inhibitor of the Histone Methyltransferase SETD2 Suitable for Preclinical Studies
por: Lampe, John W., et al.
Publicado: (2021)

The dynamic conformational landscape of the protein methyltransferase SETD8
por: Chen, Shi, et al.
Publicado: (2019)

Loss of histone methyltransferase SETD1B in oogenesis results in the redistribution of genomic histone 3 lysine 4 trimethylation
por: Hanna, Courtney W, et al.
Publicado: (2022)

Knockdown of Histone Methyltransferase hSETD1A Inhibits Progression, Migration, and Invasion in Human Hepatocellular Carcinoma
por: Cheng, Xin-sheng, et al.
Publicado: (2016)

Cellular milieu in clear cell renal cell carcinoma
por: Raghubar, Arti M., et al.
Publicado: (2022)

Insights into the stereoselectivity of human SETD7 methyltransferase
por: Tang, Bowen, et al.
Publicado: (2019)

SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12
por: González-Rodríguez, Patricia, et al.
Publicado: (2020)

PAK4 methylation by the methyltransferase SETD6 attenuates cell adhesion
por: Vershinin, Zlata, et al.
Publicado: (2020)

Histone-lysine N-methyltransferase SETD7 is a potential serum biomarker for colorectal cancer patients
por: Duan, Baojun, et al.
Publicado: (2018)

Canine osteosarcoma genome sequencing identifies recurrent mutations in DMD and the histone methyltransferase gene SETD2
por: Gardner, Heather L., et al.
Publicado: (2019)

Identification of a novel target of SETD1A histone methyltransferase and the clinical significance in pancreatic cancer
por: Ishii, Takeshi, et al.
Publicado: (2022)

Development and validation of a novel immunotype for prediction of overall survival in patients with clear cell renal cell carcinoma
por: Yu, Deshui, et al.
Publicado: (2022)

The role of immunotherapy in non-clear cell renal cell carcinoma
por: Climent, Carla, et al.
Publicado: (2023)

Development of genomic instability-associated long non-coding RNA signature: A prognostic risk model of clear cell renal cell carcinoma
por: Jiang, Dongfang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_t2s155vb3dvbl2nupjn08f98r5